Recombinant hirudin in clinical practice: focus on lepirudin
Research article published in Circulation (2001)
Abstract
Clinical applications for recombinant hirudins have been investigated for the past 10 years. The first indication for which a hirudin-lepirudin-has been approved is treatment of heparin-induced thrombocytopenia (HIT). Also, the recently completed trials for use of lepirudin in unstable angina indicate a potentially new indication. This review describes pharmacology and clinical applications of lepirudin with an emphasis on HIT and unstable angina. An overview of usage of lepirudin in acute coronary syndromes is given, as well as a summary of rare indications for lepirudin, such as extracorporeal circulation, for which comprehensive data are lacking.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Zusammenfassung
Clinical applications for recombinant hirudins have been investigated for the past 10 years. The first indication for which a hirudin-lepirudin-has been approved is treatment of heparin-induced thrombocytopenia (HIT).
Warum dies für die Hirudotherapie relevant ist
Relevant to the development and clinical application of leech-derived pharmaceutical compounds.
Zitation
Recombinant hirudin in clinical practice: focus on lepirudin.
Greinacher A, Lubenow N · Circulation, 2001
Verwandter klinischer Kontext
Erfahren Sie, wie diese Forschung mit der klinischen Praxis verknüpft ist
Zur ASH-Bibliothek hinzugefügt: March 18, 2026 · Letzte Aktualisierung der Website: June 18, 2026